Clinical Trial Update: Docetaxel in the Treatment of Hormone Refractory Prostate Cancer [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating docetaxel for hormone-refractory prostate cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Docetaxel (Taxotere) (docetaxel)

Snippet

Sponsor: Sanofi | Conditions: Prostatic Neoplasms | Phase 4 | Status: COMPLETED